Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Le Gars

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
British Journal of Clinical Pharmacology|September 27, 2024
Modelling antibody dynamics in humans after different Ad26.COV2.S vaccination schemesAnna Dari, Juan José Pérez Ruixo, Mathieu Le Gars, et al.
Immunological Reviews|June 11, 2022
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccineMathieu Le Gars, Jenny Hendriks, Jerald Sadoff, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2016
Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic DisseminationMathieu Le Gars, Michel Haustant, Maria Klezovich-Bénard, et al.
Medecine Sciences : M/S|June 15, 2017
[iNKT cells: potential therapeutic targets to fight anthrax]Mathieu Le Gars, Michel Haustant, Maria Klezovich-Benard, et al.
Vaccine|February 2, 2023
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in JapanYumi Tsuchiya, Hiroshi Tamura, Koji Fujii, et al.
Vaccine|August 9, 2024
Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease riskSanne Roels, Matthias Bruckner, Jerald Sadoff, et al.
BMC Bioinformatics|March 23, 2021
CytoGLMM: conditional differential analysis for flow and mass cytometry experimentsChristof Seiler, Anne-Maud Ferreira, Lisa M Kronstad, et al.
Ebiomedicine|May 5, 2026
Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infectionVeronica V Rezelj, Jeroen Tolboom, Nina Hertoghs, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 16, 2023
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humansAnna Dari, Philippe Jacqmin, Yuki Iwaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killingDelphyne Descamps, Mathieu Le Gars, Viviane Balloy, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|September 27, 2024
Modelling antibody dynamics in humans after different Ad26.COV2.S vaccination schemesAnna Dari, Juan José Pérez Ruixo, Mathieu Le Gars, et al.
Immunological Reviews|June 11, 2022
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccineMathieu Le Gars, Jenny Hendriks, Jerald Sadoff, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2016
Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic DisseminationMathieu Le Gars, Michel Haustant, Maria Klezovich-Bénard, et al.
Medecine Sciences : M/S|June 15, 2017
[iNKT cells: potential therapeutic targets to fight anthrax]Mathieu Le Gars, Michel Haustant, Maria Klezovich-Benard, et al.
Vaccine|February 2, 2023
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in JapanYumi Tsuchiya, Hiroshi Tamura, Koji Fujii, et al.
Vaccine|August 9, 2024
Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease riskSanne Roels, Matthias Bruckner, Jerald Sadoff, et al.
BMC Bioinformatics|March 23, 2021
CytoGLMM: conditional differential analysis for flow and mass cytometry experimentsChristof Seiler, Anne-Maud Ferreira, Lisa M Kronstad, et al.
Ebiomedicine|May 5, 2026
Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infectionVeronica V Rezelj, Jeroen Tolboom, Nina Hertoghs, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 16, 2023
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humansAnna Dari, Philippe Jacqmin, Yuki Iwaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killingDelphyne Descamps, Mathieu Le Gars, Viviane Balloy, et al.
Pageof 5